CD45RB is a novel molecular therapeutic target to inhibit Aβ peptide-induced microglial MAPK activation

PLoS ONE

Volumn 3, Issue 5, 2008, Pages

  Zhu, Yuyan ^a   Hou, Huayan ^a   Nikolic, William V ^a   Ehrhart, Jared ^a   Rrapo, Elona ^a   Bickford, Paula ^a   Giunta, Brian ^a   Tan, Jun ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; CD45 ANTIGEN; CD45RB ANTIGEN; FLUORESCEIN ISOTHIOCYANATE; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; NOOTROPIC AGENT; PROTEIN TYROSINE PHOSPHATASE; PROTEIN TYROSINE PHOSPHATASE INHIBITOR; TUMOR NECROSIS FACTOR ALPHA;

ALZHEIMER DISEASE; ANIMAL CELL; ANTIGEN PRESENTATION; ARTICLE; CELL ACTIVATION; CELL CULTURE; CONTROLLED STUDY; CROSS LINKING; CYTOKINE RELEASE; DRUG RESEARCH; DRUG TARGETING; ENZYME ACTIVATION; ENZYME INHIBITION; INHIBITION KINETICS; MICROGLIA; MOUSE; NEUROTOXICITY; NONHUMAN; PHAGOCYTOSIS; PHENOTYPE; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION; ANIMAL; BAGG ALBINO MOUSE; CULTURE MEDIUM; DRUG ANTAGONISM; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYMOLOGY; FLUORESCENCE MICROSCOPY; METABOLISM; PHYSIOLOGY; WESTERN BLOTTING;

AMYLOID BETA-PROTEIN; ANIMALS; ANTIGENS, CD45; BLOTTING, WESTERN; CULTURE MEDIA; ENZYME ACTIVATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; INTERLEUKIN-6; MICE; MICE, INBRED BALB C; MICROGLIA; MICROSCOPY, FLUORESCENCE; MITOGEN-ACTIVATED PROTEIN KINASES; PHAGOCYTOSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 47749109491     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0002135     Document Type: Article

References (63)

1. Dickson DW (1997) Neuropathological diagnosis of Alzheimer's disease: a perspective from longitudinal clinicopathological studies. Neurobiol Aging 18: S21-26.
2. Funamoto S, Morishima-Kawashima M, Tanimura Y, Hirotani N, Saido TC, et al. (2004) Truncated carboxyl-terminal fragments of beta-amyloid precursor protein are processed to amyloid beta-proteins 40 and 42. Biochemistry 43: 13532-13540.
3. Golde TE, Eckman CB, Younkin SG (2000) Biochemical detection of Abeta isoforms: implications for pathogenesis, diagnosis, and treatment of Alzheimer's disease. Biochim Biophys Acta 1502: 172-187.
4. Bradt BM, Kolb WP, Cooper NR (1998) Complement-dependent proinflammatory properties of the Alzheimer's disease beta-peptide. J Exp Med 188: 431-438.
5. Townsend KP, Town T, Mori T, Lue LF, Shytle D, et al. (2005) CD40 signaling regulates innate and adaptive activation of microglia in response to amyloid beta-peptide. Eur J Immunol 35: 901-910.
6. Fiala M, Cribbs DH, Rosenthal M, Bernard G (2007) Phagocytosis of amyloidbeta and inflammation: two faces of innate immunity in Alzheimer's disease. J Alzheimers Dis 11: 457-463.
7. Van Eldik LJ, Thompson WL, Ralay Ranaivo H, Behanna HA, Martin Watterson D (2007) Glia proinflammatory cytokine upregulation as a therapeutic target for neurodegenerative diseases: function-based and target-based discovery approaches. Int Rev Neurobiol 82: 277-296.
8. Breitner JC (1996) Inflammatory processes and antiinflammatory drugs in Alzheimer's disease: a current appraisal. Neurobiol Aging 17: 789-794.
9. Breitner JC (1996) The role of anti-inflammatory drugs in the prevention and treatment of Alzheimer's disease. Annu Rev Med 47: 401-411.
10. Launer L (2003) Nonsteroidal anti-inflammatory drug use and the risk for Alzheimer's disease: dissecting the epidemiological evidence. Drugs 63: 731-739.
11. Townsend KP, Vendrame M, Ehrhart J, Faza B, Zeng J, et al. (2004) CD45 isoform RB as a molecular target to oppose lipopolysaccharide-induced microglial activation in mice. Neurosci Lett 362: 26-30.
12. Tan J, Town T, Paris D, Mori T, Suo Z, et al. (1999) Microglial activation resulting from CD40-CD40L interaction after beta-amyloid stimulation. Science 286: 2352-2355.
13. Tan J, Town T, Saxe M, Paris D, Wu Y, et al. (1999) Ligation of microglial CD40 results in p44/42 mitogen-activated protein kinase-dependent TNF-alpha production that is opposed by TGF-beta 1 and IL-10. J Immunol 163: 6614-6621.
14. Tan J, Town T, Mullan M (2000) CD45 inhibits CD40L-induced microglial activation via negative regulation of the Src/p44/42 MAPK pathway. J Biol Chem 275: 37224-37231.
15. Yang Y, Wilson JM (1996) CD40 ligand-dependent T cell activation: requirement of B7-CD28 signaling through CD40. Science 273: 1862-1864.
16. Hermiston ML, Xu Z, Weiss A (2003) CD45: a critical regulator of signaling thresholds in immune cells. Annu Rev Immunol 21: 107-137.
17. Cosenza-Nashat MA, Kim MO, Zhao ML, Suh HS, Lee SC (2006) CD45 isoform expression in microglia and inflammatory cells in HIV-1 encephalitis. Brain Pathol 16: 256-265.
18. Stein VM, Baumgartner W, Schroder S, Zurbriggen A, Vandevelde M, et al. (2007) Differential expression of CD45 on canine microglial cells. J Vet Med A Physiol Pathol Clin Med 54: 314-320.
19. Irie-Sasaki J, Sasaki T, Matsumoto W, Opavsky A, Cheng M, et al. (2001) CD45 is a JAK phosphatase and negatively regulates cytokine receptor signalling. Nature 409: 349-354.
20. Irie-Sasaki J, Sasaki T, Penninger JM (2003) CD45 regulated signaling pathways. Curr Top Med Chem 3: 783-796.
21. Sasaki T, Sasaki-Irie J, Penninger JM (2001) New insights into the transmembrane protein tyrosine phosphatase CD45. Int J Biochem Cell Biol 33: 1041-1046.
22. Streuli M, Hall LR, Saga Y, Schlossman SF, Saito H (1987) Differential usage of three exons generates at least five different mRNAs encoding human leukocyte common antigens. J Exp Med 166: 1548-1566.
23. Tan J, Town T, Abdullah L, Wu Y, Placzek A, et al. (2002) CD45 isoform alteration in CD4+ T cells as a potential diagnostic marker of Alzheimer's disease. J Neuroimmunol 132: 164-172.
24. Masliah E, Mallory M, Hansen L, Alford M, Albright T, et al. (1991) Immunoreactivity of CD45, a protein phosphotyrosine phosphatase, in Alzheimer's disease. Acta Neuropathol (Berl) 83: 12-20.
25. Karp HL, Tillotson ML, Soria J, Reich C, Wood JG (1994) Microglial tyrosine phosphorylation systems in normal and degenerating brain. Glia 11: 284-290.
26. Bard F, Cannon C, Barbour R, Burke RL, Games D, et al. (2000) Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 6: 916-919.
27. Tan J, Town T, Mori T, Wu Y, Saxe M, et al. (2000) CD45 opposes beta-amyloid peptide-induced microglial activation via inhibition of p44/ 42 mitogen-activated protein kinase. J Neurosci 20: 7587-7594.
28. Kaisho T, Akira S (2002) Toll-like receptors as adjuvant receptors. Biochim Biophys Acta 1589: 1-13.
29. Zhang K, Zhang L, Zhu D, Bae D, Nel A, et al. (2002) CD40-mediated p38 mitogen-activated protein kinase activation is required for immunoglobulin class switch recombination to IgE. J Allergy Clin Immunol 110: 421-428.
30. McDonald DR, Bamberger ME, Combs CK, Landreth GE (1998) beta-Amyloid fibrils activate parallel mitogen-activated protein kinase pathways in microglia and THP1 monocytes. J Neurosci 18: 4451-4460.
31. Combs CK, Johnson DE, Cannady SB, Lehman TM, Landreth GE (1999) Identification of microglial signal transduction pathways mediating a neurotoxic response to amyloidogenic fragments of beta-amyloid and prion proteins. J Neurosci 19: 928-939.
32. Licastro F, Mallory M, Hansen LA, Masliah E (1998) Increased levels of alpha-1-antichymotrypsin in brains of patients with Alzheimer's disease correlate with activated astrocytes and are affected by APOE 4 genotype. J Neuroimmunol 88: 105-110.
33. Hambleton J, McMahon M, DeFranco AL (1995) Activation of Raf-1 and mitogen-activated protein kinase in murine macrophages partially mimics lipopolysaccharide-induced signaling events. J Exp Med 182: 147-154.
34. Suttles J, Milhorn DM, Miller RW, Poe JC, Wahl LM, et al. (1999) CD40 signaling of monocyte inflammatory cytokine synthesis through an ERK1/ 2-dependent pathway. A target of interleukin (il)-4 and il-10 anti-inflammatory action. J Biol Chem 274: 5835-5842.
35. Chow A, Toomre D, Garrett W, Mellman I (2002) Dendritic cell maturation triggers retrograde MHC class II transport from lysosomes to the plasma membrane. Nature 418: 988-994.
36. Perlmutter LS, Scott SA, Barron E, Chui HC (1992) MHC class II-positive microglia in human brain: association with Alzheimer lesions. J Neurosci Res 33: 549-558.
37. Liew SC, Penfold PL, Provis JM, Madigan MC, Billson FA (1994) Modulation of MHC class II expression in the absence of lymphocytic infiltrates in Alzheimer's retinae. J Neuropathol Exp Neurol 53: 150-157.
38. Matsushima GK, Taniike M, Glimcher LH, Grusby MJ, Frelinger JA, et al. (1994) Absence of MHC class II molecules reduces CNS demyelination, microglial/macrophage infiltration, and twitching in murine globoid cell leukodystrophy. Cell 78: 645-656.
39. Minagar A, Shapshak P, Fujimura R, Ownby R, Heyes M, et al. (2002) The role of macrophage/microglia and astrocytes in the pathogenesis of three neurologic disorders: HIV-associated dementia, Alzheimer disease, and multiple sclerosis. J Neurol Sci 202: 13-23.
40. Giunta B, Ehrhart J, Townsend K, Sun N, Vendrame M, et al. (2004) Galantamine and nicotine have a synergistic effect on inhibition of microglial activation induced by HIV-1 gp120. Brain Res Bull 64: 165-170.
41. Sastre M, Klockgether T, Heneka MT (2006) Contribution of inflammatory processes to Alzheimer's disease: molecular mechanisms. Int J Dev Neurosci 24: 167-176.
42. von Bernhardi R, Ramirez G, Toro R, Eugenin J (2007) Pro-inflammatory conditions promote neuronal damage mediated by Amyloid Precursor Protein and decrease its phagocytosis and degradation by microglial cells in culture. Neurobiol Dis 26: 153-164.
43. Mackenzie IR, Munoz DG (1998) Nonsteroidal anti-inflammatory drug use and Alzheimer-type pathology in aging. Neurology 50: 986-990.
44. Dalpke AH, Schafer MK, Frey M, Zimmermann S, Tebbe J, et al. (2002) Immunostimulatory CpG-DNA activates murine microglia. J Immunol 168: 4854-4863.
45. Olsson T (1995) Cytokine-producing cells in experimental autoimmune encephalomyelitis and multiple sclerosis. Neurology 45: S11-15.
46. Swanborg RH (1995) Experimental autoimmune encephalomyelitis in rodents as a model for human demyelinating disease. Clin Immunol Immunopathol 77: 4-13.
47. Cornet A, Vizler C, Liblau R (1998) [Experimental autoimmune encephalomyelitis]. Rev Neurol (Paris) 154: 586-591.
48. Kim BO, Liu Y, Ruan Y, Xu ZC, Schantz L, et al. (2003) Neuropathologies in transgenic mice expressing human immunodeficiency virus type 1 Tat protein under the regulation of the astrocyte-specific glial fibrillary acidic protein promoter and doxycycline. Am J Pathol 162: 1693-1707.
49. Town T, Nikolic V, Tan J (2005) The microglial "activation" continuum: from innate to adaptive responses. J Neuroinflammation 2: 24.
50. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, et al. (1999) Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400: 173-177.
51. Bard F, Barbour R, Cannon C, Carretto R, Fox M, et al. (2003) Epitope and isotype specificities of antibodies to beta -amyloid peptide for protection against Alzheimer's disease-like neuropathology. Proc Natl Acad Sci U S A 100: 2023-2028.
52. Tan J, Town T, Mullan M (2002) CD40-CD40L interaction in Alzheimer's disease. Curr Opin Pharmacol 2: 445-451.
53. Ono K, Han J (2000) The p38 signal transduction pathway: activation and function. Cell Signal 12: 1-13.
54. Quon D, Wang Y, Catalano R, Scardina JM, Murakami K, et al. (1991) Formation of beta-amyloid protein deposits in brains of transgenic mice. Nature 352: 239-241.
55. Higgins JA, Sacci JB Jr., Schriefer ME, Endris RG, Azad AF (1994) Molecular identification of rickettsia-like microorganisms associated with colonized cat fleas (Ctenocephalides felis). Insect Mol Biol 3: 27-33.
56. Higgins MJ, Ficsor G, Aaron CS, Petry TW, Yu RL, et al. (1995) Micronuclei in mice treated with monocrotaline with and without phenobarbital pretreatment. Environ Mol Mutagen 26: 37-43.
57. Koistinaho M, Ort M, Cimadevilla JM, Vondrous R, Cordell B, et al. (2001) Specific spatial learning deficits become severe with age in beta -amyloid precursor protein transgenic mice that harbor diffuse beta -amyloid deposits but do not form plaques. Proc Natl Acad Sci U S A 98: 14675-14680.
58. Koistinaho M, Koistinaho J (2002) Role of p38 and p44/42 mitogen-activated protein kinases in microglia. Glia 40: 175-183.
59. Pyo H, Jou I, Jung S, Hong S, Joe EH (1998) Mitogen-activated protein kinases activated by lipopolysaccharide and beta-amyloid in cultured rat microglia. Neuroreport 9: 871-874.
60. Combs CK, Karlo JC, Kao SC, Landreth GE (2001) beta-Amyloid stimulation of microglia and monocytes results in TNFalpha-dependent expression of inducible nitric oxide synthase and neuronal apoptosis. J Neurosci 21: 1179-1188.
61. Chung H, Brazil MI, Soe TT, Maxfield FR (1999) Uptake, degradation, and release of fibrillar and soluble forms of Alzheimer's amyloid beta-peptide by microglial cells. J Biol Chem 274: 32301-32308.
62. Mitrasinovic OM, Murphy GM Jr. (2002) Accelerated phagocytosis of amyloidbeta by mouse and human microglia overexpressing the macrophage colony-stimulating factor receptor. J Biol Chem 277: 29889-29896.
63. Marambaud P, Zhao H, Davies P (2005) Resveratrol promotes clearance of Alzheimer's disease amyloid-beta peptides. J Biol Chem 280: 37377-37382.